Mechanism Exploration on the Immunoregulation of Allogeneic Heart Transplantation Rejection in Rats With Exosome miRNA and Proteins From Overexpressed IDO1 BMSCs

Abstract

Immunoregulation and indoleamine 2,3-dioxygenase 1 (IDO1) play pivotal roles in the rejection of allogeneic organ transplantation. This study aims to elucidate the immune-related functional mechanisms of exosomes (Exos) derived from bone marrow–derived mesenchymal stem cells (BMSCs) overexpressing IDO1 in the context of allogeneic heart transplantation (HTx) rejection. A rat model of allogeneic HTx was established. Exos were extracted after transfection with oe-IDO1 and oe-NC from rat BMSCs. Exos were administered via the caudal vein for treatment. The survival of rats was analyzed, and reverse transcription qualitative PCR (RT-qPCR) and immunohistochemistry (IHC) were employed to detect the expression of related genes. Histopathological examination was conducted using hematoxylin and eosin (HE) staining, and flow cytometry was utilized to analyze T-cell apoptosis. Proteomics and RNA-seq analyses were performed on Exos. The data were subjected to functional enrichment analysis using the R language. A protein interaction network was constructed using the STRING database, and miRWalk, TargetScan, and miRDB databases predicted the target genes, differentially expressed miRNAs, and transcription factors (TFs). Exos from BMSCs overexpressing IDO1 prolonged the survival time of rats undergoing allogeneic HTx. These Exos reduced inflammatory cell infiltration, mitigated myocardial damage, induced CD4 T-cell apoptosis, and alleviated transplantation rejection. The correlation between Exos from BMSCs overexpressing IDO1 and immune regulation was profound. Notably, 13 immune-related differential proteins (Anxa1, Anxa2, C3, Ctsb, Hp, Il1rap, Ntn1, Ptx3, Thbs1, Hspa1b, Vegfc, Dcn, and Ptpn11) and 10 significantly different miRNAs were identified. Finally, six key immune proteins related to IDO1 were identified through common enrichment pathways, including Thbs1, Dcn, Ptpn11, Hspa1b, Il1rap, and Vegfc. Thirteen TFs of IDO1-related key miRNAs were obtained, and a TF-miRNA-mRNA-proteins regulatory network was constructed. Exosome miRNA derived from BMSCs overexpressing IDO1 may influence T-cell activation and regulate HTx rejection by interacting with mRNA.

Keywords

heart transplantation (HTx) rejection indoleamine 2 3-dioxygenase1 (IDO1)exosomes (Exos)bone marrow–derived mesenchymal stem cells (BMSCs)immunoregulatory

Introduction

With the progression of medical technology, organ transplantation has emerged as an efficacious therapeutic modality for addressing heart, kidney, and other organ failures. The principal impediment leading to the failure and mortality of organ transplantation is rejection¹. Heart failure, stemming from cardiac dysfunction, stands as a chronic ailment with a heightened mortality rate. The pathogenic underpinnings of heart failure are intricate, encompassing factors such as hypertension, valvular and congenital heart diseases, and various risk factors². Heart transplantation (HTx) stands as the exclusive recourse for end-stage heart failure treatment. However, it comes with the risk of rejection, which occurs when the recipient’s immune system recognizes the transplanted heart as foreign and mounts an immune response against it³. Allogeneic heart transplant rejection can be broadly categorized into acute rejection (AR) and chronic rejection⁴. AR is an inflammatory response in which T lymphocytes infiltrate the transplanted heart tissue. That triggers an immune response characterized by tissue damage, inflammation, and dysfunction of the transplanted heart⁵. While, chronic rejection typically occurs months to years after HTx and is a leading cause of long-term graft failure⁶. The main characteristic of chronic rejection is the development of a condition called chronic graft vasculopathy, which leads to narrowing due to the accumulation of immune cells, smooth muscle cells, and extracellular matrix within the vessel walls, leading to reduced blood flow and oxygen supply to the heart muscle⁷. As the incidence of heart failure escalates among patients, there is an increasing demand for HTx to augment both the duration and quality of life⁸. Nonetheless, the administration of immunosuppression consistently precipitates acute graft rejection in HTx⁹. Thus, it is imperative to scrutinize the molecular mechanisms contributing to the amelioration of HTx rejection.

Immunoregulation refers to the control and balance of the immune system to maintain homeostasis. It plays a crucial role in preventing excessive immune responses that can lead to harmful inflammation and tissue damage¹⁰. The innate immune response, instigated by inflammation, invariably induces organ dysfunction, thereby exacerbating allograft rejection¹¹. Graft failure always leads death of HTx patients, while immune rejection is the main cause of graft failure, targeting the immune response is vital in HTx to recover myocardial injury¹². Myocardial injury represents the foremost challenge in HTx, wherein injury to the myocardium, coupled with the activation of innate immunity, accentuates the impairment of heart function¹³. Consequently, the immune responses of T cells assume a pivotal role in HTx rejection. Indoleamine 2,3-dioxygenase (IDO) has been validated as an inducible enzyme with immune-regulatory activities, promoting tryptophan (Trp) catabolism¹⁴. Previous investigations have indicated that enhancing IDO activation can diminish Trp products, thereby attenuating T-cell activation and proliferation through the inhibition of dendritic cell (DC) function¹⁵. IDO has been affirmed to exert a protective function in organ transplantation by inhibiting rejection responses¹⁶. Studies demonstrated that the overexpression of IDO can safeguard lung allografts by suppressing T-cell responses and fortifying an antioxidant defense system¹⁷. In addition, Hill et al.¹⁸ delineated the indispensable role of IDO expression in cardiac allograft rats governed by cytotoxic T lymphocyte–associated antigen 4 immunoglobulins (CTLA4Ig). CTLA4Ig is a vital factor in preventing allograft rejection and inducing tolerance¹⁹. IDO1 is primarily expressed in immune cells, such as DCs, macrophages, and monocytes. It plays a crucial role in immune tolerance and immune escape mechanisms by regulating the balance between immune activation and suppression^20,21. Our previous research has also affirmed that exosomes (Exos) derived from overexpression IDO1 BMSCs enhance the immunotolerance of cardiac allografts²².

Bone marrow–derived mesenchymal stem cells (BMSCs) exhibit superior regulatory capabilities in immune responses, playing a pivotal role in medicinal therapies²³. BMSC-secreted Exos play the main role in BMSC exerting therapeutic effects²⁴, which contain various biologically active ingredient, that can interact with receptors to affect the signaling of target cells and are essential in immunomodulatory effects^25,26. BMSC-derived Exos has been reported to exhibit inflammation regulation by inhibiting the nuclear factor κB (NF-κB) pathway and changing macrophages M2 polarization to exhibit immunomodulatory functions²⁷. Notably, microRNAs (miRNAs) from BMSC paracrine factors, specifically Exos, hold promise in the treatment of cardiac injuries²⁸. The confirmed potential of BMSC-derived Exos includes the promotion of cardiomyocyte proliferation, inhibition of reactive oxygen species (ROS), mitigation of cardiac injury, and preservation of cardiac function²⁹. Exos, replete with active substances such as lipids, proteins, mRNA, long non-coding RNAs (LncRNAs), and miRNAs that convey information and regulate cellular functions^30,31, assume a pivotal role in cardiac repair therapies³². LncRNA exerts function through sponging miRNAs to regulate the stability, translation, and translocation of mRNAs or is bound to proteins alone, for increasing the expression of target mRNA and involved in regulating transcriptional of nucleus and cytoplasm³³. Several studies have underscored the significance of BMSC-derived Exos in conferring cardioprotection³⁴. However, the mechanistic action of Exos derived from BMSCs overexpressing IDO1 in allogeneic HTx rejection remains elusive. This study aims to elucidate the immunomodulatory effects of miRNAs and proteins within Exos from BMSCs overexpressing IDO1, employing bioinformatics to unravel their role in allogeneic HTx rejection.

Materials and Methods

Animal and Experiment

Lewis and Wistar rats were procured from Hunan SJA Laboratory Animal Co., Ltd (No.99, Changchong Road, Longping Hi-Tech Park, Furong District, Changsha City, Hunan Province, China). The rats were maintained in a light-dark cycle at 22–24°C with ad libitum access to food and water, undergoing a 7-day adaptation period and a 12-hour fasting period prior to surgery. Wistar rats served as the donor group, while Lewis rats were designated as the recipients. BMSCs were extracted from the femur and tibia of Lewis rats, as per previously reported methods³⁵. These cells were cultured in BMSC growth medium (Cyagen Biosciences, Sunnyvale, CA, USA) supplemented with 10% foetal bovine serum (FBS, Gibco, CA, USA), and P9 cells were selected for subsequent experiments.

Cell Transfection and Extraction of Exos

Overexpressed IDO1 lentivirus obtained from China Shanghai Genechem Co., Ltd. was used to transduce BMSCs via Lipofectamine 3000 reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), following established procedures²². In short, mixed Lipofectamine 3000 reagent with overexpressed IDO1 lentivirus was in a transfection medium and incubated for 10 minutes at room temperature. After seeding the cells in the 6-hole plate under 5 × 10⁴ cells/well and allowed to reach 60–80% confluency. Then, the transfection mixture was evenly applied dropwise to the cells, cultured in a 5% CO₂ cell incubator at 37°C for 48 hours, and the transfection efficiency was detected by reverse transcription qualitative (RT-qPCR), shown in Supplemental Fig. 1.

After transfected BMSCs were collected, Exos were harvested using the Total Exosome Isolation Kit (4478359; Thermo Fisher Scientific, Waltham, MA, USA) in accordance with the manufacturer’s instructions. After processed BMSCs’ culture supernatant was collected, it was centrifuged at 2,000 × g for 30 minutes, followed by ultracentrifugation of 10,000 × g for 20 minutes for removing any cellular debris. Then, they were transferred to new tubes, and a Ribom™ Exosome isolation Reagent (Ribobio Co., Ltd, Guangzhou, China) (for cell culture media) was added and mixed well, at the 4°C refrigerator overnight. The next day, at a time, 2 mL was transferred to a new centrifuge tube, and centrifugation was performed at 15,000 × g for 30 minutes at 4°C repeatedly to extract all the mixed liquids, into pellet Exos. Subsequently, store the Exos. Transmission electron microscope (TEM, Hitachi, Japan, H7500) was employed to observe the exosome morphology, as shown in Supplemental Fig. 2.

Allogeneic HTx Model

All rats were anesthetized by isoflurane inhalation (1.5%–2%), as previously described³⁶. First, after laparotomy, 50-U/L ice heparin saline solution (5 mL) at 4°C was injected through the inferior vena cava into Wistar rats. After 2 minutes, the abdominal aorta and inferior vena cava were cut for adequate bleeding. Subsequently, the thorax was opened, salt water for ice was cut, and a single 5-0 ligature was used to ligate the inferior and superior vena cava. The aortic and pulmonary arteries were cut, and the pulmonary vein of the heart was ligated and removed heart. Simultaneously, the abdomen of Lewis rats was opened, abdominal aorta and inferior vena cava were separated, and the heart from donor rats was implanted. The continuous single-point fitting method was employed to connect the aorta to the abdominal aorta and the pulmonary artery to the inferior vena cava. Analgesia was administered perioperatively using carprofen. Survival status was recorded daily, and mortality was calculated by Kaplan-Meier test. Exos (5 μg/mL) from each group were administered through the caudal vein 2 mL and categorized into the Model group (HTx rats), the BMSC group (HTx rats + Exos from BMSC), the NC group (HTx rats + Exos from transfected oe-NC BMSC), and the IDO1 group (HTx rats + Exos from transfected oe-IDO1 BMSC). The survival time of Lewis rats was analyzed using log-rank (Mantel-Cox) testing.

Reverse Transcription Qualitative PCR

Total RNA from rat heart tissues in each group was extracted using TRIzol reagent (Invitrogen, 15596026) and reverse transcribed to cDNA using the One Step Prime Script miRNA cDNA Synthesis Kit (Takara, Kyoto, Japan). RT-qPCR was performed using SYBR Green PCR Master Mix (Life Technologies, CA, USA) following the manufacturer’s protocols. The primers used for RT-qPCR are detailed in Table 1. The relative expression was calculated using the 2-ΔΔCt method, with GAPDH or U6 serving as the internal reference.

Table 1.

PCR Primer Sequence.

Genes	Primer	Sequence (5’-3’)
IDO1	Forward	5’-CAATCTTGCCGTTCCCTAC-3’
IDO1	Reverse	5’-TCCACGAAGTCACGCATC-3’
Anxa1	Forward	5’-CCTTCCTTCAATCCGTCCTC-3’
Anxa1	Reverse	5’-GCCCTGGCATCTGTATCA-3’
Anxa2	Forward	5’-GGACATTGCCTTCGCCTAC-3’
Anxa2	Reverse	5’-CCTCTGCCCGTTTACCCT-3’
C3	Forward	5’-GCGGAAGTGTTGTGAGGA-3’
C3	Reverse	5’-AGTAGGGCAGTCGCAGGT-3’
Ctsb	Forward	5’-GAAAGGGTTGGGTTCAGC-3’
Ctsb	Reverse	5’-GGAGTAGCCAGCCTCACA-3’
Dcn	Forward	5’-TTCGACTCCACGACAATG-3’
Dcn	Reverse	5’-TTCCACAACGGTGATGCT-3’
Hp	Forward	5’-CCTATCTGCCTGCCTTCC-3’
Hp	Reverse	5’-AGGTGTCCTCCTCCGTGTC-3’
Hspa1b	Forward	5’-TGCCCGCCTACTTCAACG-3’
Hspa1b	Reverse	5’-GAACAGGTCCGAGCACAGCT-3’
Il1rap	Forward	5’-TCTACTCGCCAAATGACC-3’
Il1rap	Reverse	5’-ATCTCCAGCCAGTAAACG-3’
Ntn1	Forward	5’-TTTGGCGACGAGAACGAA-3’
Ntn1	Reverse	5’-GCGGCAGTTGAGACAGACAC-3’
Ptpn11	Forward	5’-CTTCTGGCGGATGGTGTT-3’
Ptpn11	Reverse	5’-CTCGGATGATGTCAATAAGGAT-3’
Ptx3	Forward	5’-TTTTCTTCCCAATGCGTTCT-3’
Ptx3	Reverse	5’-CCTTATCTCCTCCTTGCTGA-3’
Thbs1	Forward	5’-CTGCCATCCGCACCAACT-3’
Thbs1	Reverse	5’-ACCAGGGAGACCAGCCATC-3’
Vegfc	Forward	5’-GGCGAGGTCAAGGGTTTC-3’
Vegfc	Reverse	5’-TGCACCGGCAGGAAGTGT-3’
GAPDH	Forward	5’-TGACCACAGTCCATGCCATCAC-3’
	Reverse	5’-CGCCTGCTTCACCACCTTCTT-3’
rno-let-7a-1-3p	Forward	5’-GGAGAAACAACAACACGCCC-3’
rno-let-7a-1-3p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-let-7b-5p	Forward	5’-CGAAGAAACAACAACCACGC-3’
rno-let-7b-5p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-let-7c-2-3p	Forward	5’-AACAACAACACGCCCGAAG-3’
rno-let-7c-2-3p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-let-7f-2-3p	Forward	5’-CGGAGAAACAACAGCACGC-3’
rno-let-7f-2-3p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-let-7f-5p	Forward	5’-CGCGCGTGAGGTAGTAGATTGT-3’
rno-let-7f-5p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-let-7i-5p	Forward	5’-AGAAACGCGCAAGCACG-3’
rno-let-7i-5p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-miR-106b-5p	Forward	5’-GCACGGGGACGCGCCC-3’
rno-miR-106b-5p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-miR-10a-3p	Forward	5’-CAGGGGAAAGAGGACAAAACAC-3’
rno-miR-10a-3p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-miR-10a-5p	Forward	5’-CAGGGGAAAGAGGACAAAACAC-3’
rno-miR-10a-5p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
rno-miR-10b-5p	Forward	5’-GGGGAAAAGGCGAGCAA-3’
rno-miR-10b-5p	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’
U6	Forward	5’-CAAATTCGTGAAGCGTTCCA-3’
U6	Reverse	5’-AGTGCAGGGTCCGAGGTATT-3’

Histological Staining

HTx samples from each group were fixed in 4% paraformaldehyde and processed into paraffin slices. Sections were stained using the hematoxylin and eosin (HE) Stain Kit (G1120; Beijing Solebao Biotechnology Co., Ltd., China), and immunohistochemistry (IHC) was performed using the anti-IDO1 antibody (1:2,000; ab311847, Abcam, UK) to assess pathology and IDO1 expression.

Flow Cytometry

After concluding the experiment, spleens from each group were collected to isolate T lymphocytes. CD4+ T cells were extracted using the Stemcell 16052 StemSepTM Rat CD4+ T Cell Enrichment Kit (HY-001068; Shanghai Yes Service Biotech, Inc., China) following the product manual. The rate of programmed cell death was determined using the Annexin-V-FITC/PI apoptosis kit from Absin, a Chinese company, and assessed by FACScan flow cytometry.

Data Sources

Exos extracted through the methods outlined in “2.2 Cell Transfection and Extraction of Exosomes” were utilized as data sources. The BMSC group comprised Exos from normal BMSCs, the NC group included Exos from transfected oe-NC BMSC, and the IDO1 group involved Exos from transfected oe-IDO1 BMSC. Proteomics and RNA-seq analyses were conducted for further insights.

Extracted Protein and Trypsin Digestion

HTx samples from each group were collected, and Radio Immunoprecipitation Assay (RIPA) buffer (Sigma-Aldrich, St. Louis, MO, USA) with 1% protease and phosphatase inhibitor was added to extract total proteins. Following the previously mentioned method, the protein concentration was determined. A 100-mg protein solution underwent reduction with 90 μL of 10-mmol/L tris (2-carboxyethyl) phosphine (TCEP, Thermo Fisher) at 37°C for 30 minutes. Subsequently, 40 mmol/L iodoacetamide was added for alkylation in darkness for 40 minutes. Alkylated samples were then precipitated with cooled acetone at −20°C for 4 hours, followed by centrifugation at 10,000 × g/min at 4°C for 20 minutes. The protein samples were diluted in 50-mmol/L triethylammonium bicarbonate (TEAB), and trypsin/protein digestion was carried out twice³⁷.

TMT Peptide Labeling and Mass Spectrometric Analysis

The three groups (BMSC group, NC group, and IDO1 group) were collected for proteomic analysis. Peptides were dissolved with 0.5m TEAB and labeled using the 6-label TMT kit (Thermo Fisher Scientific), following the kit’s instructions. Fractionation of peptides was performed using high-pH reverse high-performance liquid chromatography (HPLC) with an Agilent 300Extend C18 column (2.1 mm 100 mm, 3.5 μm, Agilent, USA). Peptide analysis was carried out using LTQ Orbitrap Elite, following the methods described by Stryiński et al.³⁸

Obtaining Differential miRNA by miRNA Chip

Total RNA from the three groups (BMSC group, NC group, and IDO1 group) was collected. The total RNA quality was assessed by formaldehyde denatured gel electrophoretic assay and purified using the mirVana purification miRNA Isolation Kit (AM1561). Dephosphorylation and labeling reactions were performed using the miRNA Complete Labeling and Hyb Kit from Agilent. After hybridisation, washing, and drying the slides, the hybrid image was obtained using the Agilent chip scanner (G2565CA). The Agilent Feature Extraction (v10.7) software was employed to analyze the hybrid images and extract the data.

Principal Component Analysis

Principal component analysis (PCA) represents a widely utilized algorithm for data dimensionality reduction. All samples from the BMSC group, NC group, and IDO1 group were included in the PCA analysis to visualize the degree of separation, which was accomplished with scatterplot3d package (v0.3-43)³⁹.

Differentially Expressed Gene Analysis

Differentially expressed proteins (DEPs) between the IDO1 group and BMSC group (DEP1) and between the BMSC group and NC group (DEP2) were acquired using the limma⁴⁰ package (v3.44.3) with screening thresholds of|logFC| > 0.5 and P < 0.05. Meanwhile, differentially expressed miRNAs (DEmiRNAs) between the IDO1 group and BMSC group (DEmiRNA1) and BMSC group and NC group (DEmiRNA2) were filtered by the DESeq2⁴¹ package (v1.42.0). The screening criteria were set as|logFC| > 0.5, and P < 0.05. DEPs and DEmiRNAs were shown through volcano map and heatmap, which were plotted by ggplot2⁴² and pheatmap⁴³ packages, respectively.

Obtained Immune-Related Genes

The study methods of Chen et al.⁴⁴ were referenced to obtain immune-related genes (IRGs) from the ImmPort and InnateDB databases, as detailed in Supplemental Table 1.

Functional Enrichment Analysis

The clusterProfiler⁴⁵ package (v1.58.0) was utilized for gene ontology (GO)⁴⁶ and Kyoto Encyclopedia of Genes and Genomes (KEGG)⁴⁷ enrichment analyses of DEPs and miRNAs, with significance determined at adj. P < 0.05.

Protein Interaction Network

The protein-protein interaction (PPI) network was constructed using the STRING database (https://cn.string-db.org/) and visualized using Cytoscape (v 3.6.1)⁴⁸, with subsequent screening of proteins for further analysis.

Target Gene Prediction and GeneMANIA Network Construction

Prediction of target genes for DEmiRNAs associated with IDO1 was performed using miRanda and miRDB databases. GeneMANIA was employed for predicting interactions, functional enrichment in networks, and pathways of key proteins related to IDO1. In addition, transcription factors (TFs) were predicted using the miRDB and miRWalk databases.

Statistical Analysis

All experimental data are presented as mean ± standard deviation (mean ± SD). GraphPad Prism 8 facilitated data analysis and plotting. T-tests were employed for comparisons between two groups, one-way analysis of variance (one-way ANOVA) for comparisons among groups, and two-way analysis of variance (two-way ANOVA) for pairwise comparisons between groups. P values <0.05 indicated statistical significance.

Results

Exos From Overexpression IDO1 BMSCs Can Effectively Relieve Allogeneic HTx Rejection in Rats

Initially, we established an allogeneic HTx model in rats, observing that the model group exhibited the shortest survival time after transplantation. While no significant difference was discerned between the BMSC group and NC group, the IDO1 group demonstrated a noteworthy extension in survival time (Fig. 1A). The expression of IDO1 was notably diminished in the model group, whereas the administration of Exos from BMSCs overexpressing IDO1 substantially elevated IDO1 expression, as validated by RT-qPCR and IHC (Fig. 1B, C). Histopathological analysis using HE staining revealed marked inflammatory cell infiltration, disorganization, diminished cardiomyocytes, and severe myocardial damage in the model group. The BMSC and NC groups exhibited similar outcomes, whereas the IDO1 group exhibited reduced inflammatory cell infiltration, a little vacuolation between myocardial cells and diminished myocardial damage (Fig. 1D). Flow cytometry analysis indicated a higher CD4 T-cell apoptosis rate in the BMSC group than the model group, with no significant difference from the NC group. Notably, the IDO1 group significantly promoted CD4 T-cell apoptosis (Fig. 1E). These findings collectively suggest that Exos derived from BMSCs overexpressing IDO1 enhance the survival time in allogeneic HTx in rats and mitigate rejection by inducing CD4 T-cell apoptosis.

Figure 1.

Exos from overexpression IDO1 BMSCs can effectively relieve allogeneic heart transplantation rejection in rats. (A) Kaplan-Meier analysis of the survival of rats. (B) RT-qPCR detected expression of IDO1. (C) IHC detected the expression of IDO1. (D) Histopathological examination by HE. (E) Flow cytometry analysis T-cell apoptosis. ***P < 0.01, compared with the model group; ^###P < 0.01, compared with the BMSC group.

Analysis of Immune-Related Differential Proteins in Exos of Rats BMSC

To elucidate the mechanism through which Exos from BMSCs overexpressing IDO1 alleviate HTx rejection in rats, we conducted proteomics analysis. PCA analysis revealed a distinct separation among the IDO1 group, BMSC group, and NC group, displaying no anomalies (Fig. 2A). Employing the limma package, we identified 169 differentially expressed proteins (DEP1) between the IDO1 and BMSC groups (Fig. 2B, C), as well as seven differentially expressed proteins (DEP2) between the NC and BMSC groups (Fig. 2D, E); detailed results are provided in Supplemental Table 2. Upon eliminating common proteins from DEP1 and DEP2, we obtained 162 DEPs (Fig. 2F), which intersected with 1,697 IRGs (Supplemental Table 1). Consequently, 13 immune-related differential proteins were identified as key proteins (Fig. 2G), encompassing C3, Ptx3, Hspa1b, Ntn1, Thbs1, Anxa2, Ctsb, Il1rap, Vegfc, Anxa1, Dcn, Ptpn11, and Hp.

Figure 2.

Analysis of immune-related differential proteins in exosomes of rats BMSC. (A) Proteomics dataset principal component analysis (PCA). (B and D) Volcano maps of differential protein expression: The x-axis depicts multiple log2FC of differential expression, while the y-axis represents −log10 (P value). Each point on the map corresponds to a gene, with red indicating a significantly upregulated gene, green denoting a significantly downregulated gene, and gray representing a nonsignificant gene. (C and E) Heat Maps of differential protein expression: The upper section displays the gene distribution heat map, and the lower section depicts the gene expression heat map. The x-axis represents the samples, and the y-axis represents the differentially expressed genes. The color scale indicates standardized gene expression, where red signifies high expression and blue indicates low expression. Each sample is representative of sample grouping. (F) Venn Diagram of intersecting immune-related differential proteins.

Functional Enrichment Analysis and Expression Identification of Immune-Related Differential Proteins

Using the clusterProfiler package with an adjusted P value threshold of <0.05, we conducted KEGG and GO enrichment analyses of immune-related differential proteins. The results are presented in Fig. 3A, B, showcasing the top five enriched terms. In total, 818 GO terms were identified (Supplemental Table 3), comprising 717 biological process (BP) terms (such as peptide cross-linking, response to mechanical stimulus, epithelial cell migration, epithelium migration, and tissue migration), 40 cellular component (CC) terms (including extracellular matrix, external encapsulating structure, membrane raft, membrane microdomain, and sarcolemma), and 61 molecular function (MF) terms (like extracellular matrix binding, collagen binding, lipase inhibitor activity, calcium-dependent phospholipid binding, and phosphatidylserine binding).

Figure 3.

Functional enrichment analysis and expression identification of immune-related differential proteins. (A–B) GO enrichment and KEGG analysis of immune-related differential proteins. The connecting lines represent pathways and significantly enriched genes, with small dots on the left half denoting genes and large dots on the right half representing pathways. (C) Box plots of immune-related differential protein expression compared to the BMSC group. (*P < 0.05, **P < 0.01, ***P < 0.001). (D) Protein-protein interaction (PPI) network.

In the KEGG pathway analysis, 10 functional pathways were enriched (Supplemental Table 4), encompassing proteoglycans in cancer, mitogen-activated protein kinase (MAPK) signaling pathway, antigen processing and presentation, transforming growth factor beta (TGF-beta) signaling pathway, and Axon guidance. The expression levels of immune-related differential proteins between the IDO1 and BMSC groups were evaluated using box diagrams, revealing the results shown in Fig. 3C. Relative to the BMSC group, the expression levels of Anxa1, Anxa2, C3, Ctsb, Hp, Il1rap, Ntn1, Ptx3, and Thbs1 were downregulated, while Hspa1b, Vegfc, Dcn, and Ptpn11 were upregulated. Utilizing the STRING database, a total of 10 nodes and 12 edges were obtained in the PPI network (Fig. 3D).

Analysis of Differential miRNAs in Rat BMSC Exos

We conducted a comprehensive analysis of differential miRNAs in Exos derived from BMSCs overexpressing IDO1. PCA analysis revealed distinct separation among the IDO1, BMSC, and NC groups, with no anomalies in the miRNA sequencing datasets (Fig. 4A). Using the DESeq2 package, we identified 425 differentially expressed miRNAs (DEmiRNA1) between the IDO1 and BMSC groups (Supplemental Table 5), as shown in Fig. 4B, C, and 380 differentially expressed miRNAs (DEmiRNA2) between the NC and BMSC groups (Supplemental Table 6), as depicted in Fig. 4D, E. Employing a significance threshold of P-value <0.05 and |logFC| > 0.5, we obtained 157 DEmiRNA1 (Supplemental Table 7) and 87 DEmiRNA2 (Supplemental Table 8). After excluding common miRNAs from DEmiRNA1 and DEmiRNA2, we identified 107 DEmiRNAs (Fig. 4F). Detailed results can be found in Supplemental Table 9.

Figure 4.

Analysis of differential miRNAs in exosomes of rat BMSCs. (A) PCA of miRNA-seq datasets. (B and D) Volcano plots of Differential miRNA expression. The abscissa represents the log2FC of differential expression, while the ordinate represents the −log10 (P value). Each point signifies a miRNA, with red denoting significantly upregulated miRNA, green indicating significantly downregulated miRNA, and gray representing non-significant miRNA. (C and E) Heatmaps of differential miRNA expression. The top section illustrates the distribution of miRNAs, and the bottom section presents the expression levels. The abscissa represents the sample, while the ordinate represents the differential expression of miRNA. Color indicates standardized miRNA expression, with red signifying high expression and blue indicating low expression. Sample grouping is represented along the axes. (F) Venn Diagram of differential miRNA intersections.

Expression Identification, Target Gene Prediction, and Functional Enrichment Analysis of IDO1-Related Differential miRNAs

We assessed the expression levels of IDO1-related miRNAs between the IDO1 and BMSC groups in rat BMSC Exos using a box plot (Supplemental Table 10). Only miRNAs exhibiting significant differences were retained as IDO1-related differential miRNAs for subsequent analysis (Supplemental Table 11). The top 10 miRNAs are depicted in Fig. 5A, with all 10 showing downregulation compared to the BMSC group (Supplemental Table 12).

Figure 5.

Expression identification, target gene prediction, and functional enrichment analysis of IDO1-related differential miRNAs. (A) Box plot illustrating the expression of IDO1-related differential miRNAs compared to the BMSC group. *P < 0.05, **P < 0.01, ***P < 0.001. (B) Venn diagram displaying mRNA intersections of IDO1-related differential miRNAs. (C) Relationship network illustrating mRNA interactions with IDO1-related differential miRNAs. (D–E) GO enrichment and KEGG analysis of immune-related differential proteins. The connecting lines represent pathways and genes that were significantly enriched, with small dots on the left half denoting genes and large dots on the right half representing pathways.

Target genes (mRNAs) of IDO1-related differential miRNAs were predicted using miRanda and miRDB databases (Supplemental Table 13). The intersection of miranda and IRGs yielded 34 immune mRNAs related to IDO1 differential miRNAs (Supplemental Table 14), as illustrated in Fig. 5B. The target relationship between immune mRNAs of IDO1-related differential miRNAs and IDO1-related differential miRNAs is presented in Fig. 5C (see Supplemental Table 15 for detailed results).

Subsequently, KEGG and GO enrichment analyses were performed on these immune mRNAs of IDO1-related differential miRNAs. The top 5 results are shown in Fig. 5D, E. A total of 1,543 GO terms were obtained (Supplemental Table 16), encompassing 1,364 BP terms (e.g., response to ROS, response to hydrogen peroxide, regulation of DNA-binding TF activity, regulation of inflammatory response, and cellular response to chemical stress), 73 CC terms (e.g., secretory granule, protein serine/threonine phosphatase complex, phosphatase complex, midbody, and sperm plasma membrane), and 107 MF terms (e.g., transcription coregulator binding, RNA polymerase II-specific DNA-binding TF binding, cytokine activity, phosphatase binding, and transcription coactivator binding). In addition, 72 functional pathways were enriched in KEGG (Supplemental Table 17), including lipid and atherosclerosis, vascular smooth muscle contraction, renin secretion, fluid shear stress and atherosclerosis, and oxytocin signaling pathway.

Analysis and Identification of Key miRNAs and Key Proteins

Common enrichment pathways between IDO1-related immune proteins and immune mRNAs of IDO1-related miRNAs were selected as key pathways (Fig. 6A). These include proteoglycans in cancer, MAPK signaling pathway, Ras signaling pathway, and PI3K-Akt signaling pathway (Supplemental Table 18). Six IDO1-related immune proteins within these key pathways were identified as IDO1-related key proteins (Fig. 6B): Thbs1, Dcn, Ptpn11, Hspa1b, Il1rap, and Vegfc (Supplemental Table 19). Twenty-three IDO1-related miRNAs corresponding to immune mRNAs in key pathways were identified as key IDO1-related miRNAs (Fig. 6C): rno-miR-872-3p, rno-miR-142-5p, rno-miR-181d-5p, rno-miR-199a-5p, rno-miR-206-3p, rno-miR-218a-5p, rno-miR-455-5p, rno-miR-874-3p, rno-miR-128-3p, rno-miR-497-5p, rno-miR-92a-3p, rno-miR-15b-5p, rno-miR-195-5p, rno-miR-19b-3p, rno-miR-27a-3p, rno-miR-27b-3p, rno-miR-34b-5p, rno-miR-374-5p, rno-miR-144-3p, rno-miR-27a-5p, rno-miR-30b-5p, rno-miR-30d-5p, and rno-miR-106b-5p (Supplemental Table 20). Using GeneMANIA, we predicted the interaction and functional enrichment of IDO1-related key proteins in the network and pathways, revealing 20 interacting genes and 7 related pathways (Fig. 6D). We then predicted the TF of IDO1-related key miRNAs using miRDB and miRWalk databases, obtaining 13 TFs of IDO1-related key miRNAs. The regulatory network is shown in Fig. 6E (Supplemental Table 21), and the TF-miRNA-mRNA regulatory network (Supplemental Table 22) was constructed by combining the target relationships between IDO1-related immune mRNAs and miRNAs (Supplemental Table 15), as illustrated in Fig. 6F. Finally, we predicted the common miRNA of IDO1-related key proteins coding genes using miRWalk and miRDB databases (Supplemental Table 23) and visualized the network of key protein gene-miRNA relationships (Fig. 6G). The TF-miRNA-mRNA-proteins regulatory network was built by combining the TF-miRNA-mRNA regulatory network and the key protein gene-miRNA network (Fig. 6H).

Figure 6.

Analysis and identification of key miRNAs and key proteins. (A–C) Venn diagrams. (B) Venn diagram illustrating mRNA intersections of IDO1-related differential miRNAs. (D) IDO1-related key proteins GeneMANIA Network. (E) IDO1 TF-miRNA-mRNA network; green represents miRNA, and blue represents TF. (F) IDO1 TF-miRNA-mRNA network; red represents mRNA, green represents miRNA, and blue represents TF. (G) Sankey diagram of IDO1-related key protein networks. (H) Sankey diagram of IDO1-related key protein networks; red represents mRNA, purple represents miRNA, green represents TF, and blue represents protein.

Identification of the Expression Level of Key miRNAs and Key Proteins

Finally, we validated the expression level of key miRNAs and key proteins in the HTx rat tissues. Consistent with the aforementioned results, when compared to the BMSC group tissues, the expression of Anxa1, Anxa2, C3, Ctsb, Hp, Il1rap, Ntn1, Ptx3, and Thbs1 decreased, while Hspa1b, Vegfc, Dcn, and Ptpn11 increased in the IDO1 group tissues (Fig. 7A). In addition, the expression of 10 miRNAs decreased (Fig. 7B), including rno-let-7a-1-3p, rno-let-7b-5p, rno-let-7c-2-3p, rno-let-7f-2-3p, rno-let-7f-5p, rno-let-7i-5p, rno-miR-106b-5p, rno-miR-10a-3p, rno-miR-10a-5p, and rno-miR-10b-5p.

Figure 7.

Identification of the expression level of the key miRNAs and key proteins. (A–B) RT-qPCR detected the expression level of the key proteins and key miRNAs. *P < 0.05, **P < 0.01, ***P < 0.01, compared with the BMSC group.

Discussion

IDO, an immunosuppressive enzyme, has been established to play a pivotal role in immunoregulatory mechanisms. IDO promotes apoptosis of T cells and natural killer (NK) cells by inhibiting the concentration of Trp⁴⁹. Earlier studies have indicated that enhancing the expression of IDO can mitigate lung transplantation rejection and restore impaired T-cell activation⁵⁰. Research by Li et al.⁵¹ confirmed that IDO reduces rejection of heart-transplanted organs in mice, enhancing immune tolerance through interaction with Trp catabolic products (TC). IDO1 is crucial in various organ transplants. In transplant cells, IDO1 activated can inhibit transplant rejection and is the potential marker in rejection risk⁵². However, the mechanism of IDO1 in allogeneic HTx rejection is not fully understood yet. In our rat model of allogeneic HTx treated with Exos from transfected overexpression IDO1 BMSCs, we observed an improvement in the survival time and alleviation of transplantation rejection through the promotion of CD4 T-cell apoptosis. Consistent with our previous findings²². In this study, we delved into the immune-related functional mechanisms of Exos from overexpression IDO1 BMSCs in allogeneic HTx rejection.

Immunoregulation, a pivotal factor in allogeneic organ transplantation rejection, is crucial for enhancing immune tolerance and preventing rejection in organ transplantation recipients. Immunoregulation plays a key role in T-cell dysfunction, which often accompanies transplantation rejection⁵³. In our investigation, we identified a strong correlation between Exos from overexpression IDO1 BMSCs and immune regulation in relieving HTx rejection in rats. We pinpointed 13 immune-related key proteins, such as C3, Ptx3, Hspa1b, Ntn1, Thbs1, Anxa2, Ctsb, Il1rap, Vegfc, Anxa1, Dcn, Ptpn11, and Hp. These proteins exhibit MFs like lipase inhibitor activity, calcium-dependent phospholipid binding, and phosphatidylserine binding. They are associated with the MAPK signaling pathway and the TGF-beta signaling pathway. Previous research has demonstrated that high IDO expression can inhibit T-cell receptor (TCR) activation and T-cell activity linked to calcium release and mitochondria⁵⁰.

Exos, rich in proteins, mRNA, and miRNA, serve a crucial role in facilitating cell-to-cell communication⁵⁴. Numerous studies have highlighted the significant role of miRNA derived from BMSC Exos in cardiac protection^55,56. In this investigation, we identified DEmiRNAs in Exos from overexpression IDO1 BMSCs, including rno-let-7a-1-3p, rno-let-7b-5p, rno-let-7c-2-3p, rno-let-7f-2-3p, rno-let-7f-5p, rno-let-7i-5p, rno-miR-106b-5p, rno-miR-10a-3p, rno-miR-10a-5p, and rno-miR-10b-5p, with these 10 miRNAs exhibiting downregulation in IDO1 group tissues. Furthermore, we identified 34 immune mRNAs associated with IDO1-related differential miRNAs. MiRNAs, through complementary sequences, can bind to mRNA and play a pivotal role in cardiac remodeling and myocardial injury by regulating mRNA translation and degradation⁵⁷. Novák et al.⁵⁸ confirmed the crucial role of miRNAs in the process of heart allograft transplantation rejection, demonstrating their potential diagnostic or predictive value in rejection outcomes. Research studies have reported that let-7b-5p and let-7c are abnormal expressions in acute cellular rejection (ACR) of liver transplantation patients⁵⁹. Xu et al.⁶⁰ confirmed that miR-10a had a low expression of AR in lung transplant recipients (LTxR), the same as our results that rno-miR-10a-3p and rno-miR-10a-5p were downregulated. Subsequently, function enrichment analyses were performed on these immune mRNAs of IDO1-related differential miRNAs, finding that enrichment results mainly in the regulation of inflammatory response, lipid and atherosclerosis, TNF signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, and so on. Previous research has discovered the relationship between organ transplantation and atherosclerosis, where organ transplantation leads the development⁶¹. TNF has been confirmed as a key factor that regulates cell inflammation response and mediates tumor rejection⁶². MAPK signaling pathway plays a crucial role in the activation of T cells and participates in the immune monitoring of kidney transplant patients⁶³. The IL-17 signaling pathway is vital in the immune system. T helper cells produce IL-17, which is involved in the rejection of transplanted organs⁶⁴. Therefore, immune mRNAs of IDO1-related differential miRNAs involved in regulating HTx rejection may be related to the aforementioned immunoregulation pathway, but the specific molecular mechanisms need to be further explored.

Through the identification of common enrichment pathways, we obtained 6 IDO1-related key immune proteins, namely Thbs1, Dcn, Ptpn11, Hspa1b, Il1rap, and Vegfc. Thbs1, a member of the thrombospondins (Thbs) family, has been linked to inducing lethal cardiac atrophy when highly expressed⁶⁵. Previous studies have indicated that decorin (DCN) can alleviate cardiac dysfunction and inflammation, making it a potential treatment for diabetic cardiomyopathy⁶⁶. Research by Sznajer et al.⁶⁷ established a connection between PTPN11 gene mutation and heart defects in 85% of patients. The study by Liu et al.⁶⁸ identified Hspa1b as a key gene associated with acute myocardial infarction (AMI). IL-1 receptor accessory protein (IL1RAP) is implicated in neutrophil activity and inflammation⁶⁹. Vascular endothelial growth factor C (VEGFC) plays a vital role in cardioprotection, inhibiting proinflammatory macrophage activation and alleviating cardiac injury and inflammation⁷⁰. Consequently, we hypothesize that Exos from overexpression of IDO1 BMSCs alleviates HTx rejection through the influence of these key immune proteins. Subsequently, we predicted the interaction and functional enrichment of IDO1-related key proteins in networks and pathways, predicted the TFs, and constructed the TF-miRNA-mRNA regulatory network and TF-miRNA-mRNA-proteins regulatory network.

In conclusion, our study demonstrates that Exos from overexpression IDO1 BMSCs play a crucial role in HTx rejection, particularly through their association with immune proteins. The exosome miRNA derived from overexpression IDO1 BMSCs may impact T-cell activation and regulate HTx rejection by interacting with mRNA. The 6 IDO1-related key immune proteins (Thbs1, Dcn, Ptpn11, Hspa1b, Il1rap, and Vegfc) emerge as pivotal players in transplantation rejection and hold promise as potential biomarkers in transplant rejection.

Supplemental Material

sj-docx-1-cll-10.1177_09636897241245796 – Supplemental material for Mechanism Exploration on the Immunoregulation of Allogeneic Heart Transplantation Rejection in Rats With Exosome miRNA and Proteins From Overexpressed IDO1 BMSCs

Supplemental material, sj-docx-1-cll-10.1177_09636897241245796 for Mechanism Exploration on the Immunoregulation of Allogeneic Heart Transplantation Rejection in Rats With Exosome miRNA and Proteins From Overexpressed IDO1 BMSCs by Rui Zheng, Xinxin Wu, Si Li, Xinhao Chen, Dan Yan and Jigang He in Cell Transplantation

Footnotes

Acknowledgements

The authors acknowledge ImmPort, InnateDB, miRDB, miRWalk, Uniprot, GSEA, GEO, GO, KEGG, STRING, MSigDB, miranda, and mirdb database for providing their platforms and contributors for uploading their meaningful datasets. The authors thank their colleagues for helpful suggestions.

Author Contributions

Conceived and designed the experiments: Jigang He and Rui Zheng; performed the experiments: Jigang He, Xinxin Wu, and Xinhao Chen; analyzed the data: Dan Yan; contributed reagents/materials/analysis tools: Xinhao Chen and Si Li; writing–original draft: Xinxin Wu and Jigang He; writing–review & editing: Jigang He and Rui Zheng.

Data Availability Statement

Data are applicable after the approval of co-authors.

Ethical Approval

With the assistance of Yunnan Labreal Biotech Co., Ltd., the animal experiment was conducted and received approval from the Experimental Animal Ethics Committee of Yunnan Labreal Biotech Co., Ltd (IACUC Issue No. PZ20221110).

Statement of Human and Animal Rights

This article does not contain any studies with human or animal subjects.

Statement of Informed Consent

There are no human subjects in this article, and informed consent is not applicable.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Natural Science Foundation of China (no.: 82060299); Medical Discipline Leader Project of Yunnan Provincial Health Commission (no.: D-2019020); Yunnan Provincial Government Ten Thousand Person-Top Young Talents Project (no.: KH-SWR-QNBJ-2019-002); Clinical Medical Center of the First People’s Hospital of Yunnan Province (no.: 2021LCZXXF-XZ04); Kunming Medical Joint Special Project-Outstanding Youth Cultivation Project (no.: 202101AY070001-034); Clinical Medical Center of the First People’s Hospital of Yunnan Province (no.: 2022LCZXKF-HX05); Kunming Medical joint special project (no.: 202101AY070001-272); Famous Doctor Project of “Xingdian Talent Support Plan” of Yunnan Province (no.: XDYC-MY-2022-0037); Yunnan Province 2023 Undergraduate Education and Teaching Reform Research Project (2023BKXJJG-F04002).

ORCID iD

Jigang He

Supplemental Material

Supplemental material for this article is available online.

References

Zhou

Wang

Zhang

Geng

Deng

Cheng

Wang

. Current status of xenotransplantation research and the strategies for preventing xenograft rejection. Front Immunol. 2022;13:928173.

Mosterd

Hoes

. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46.

Miller

Daniels

Wang

Chen

Young

Wang

Yin

Husain

Alegre

, et al Spontaneous restoration of transplantation tolerance after acute rejection. Nat Commun. 2015;6:7566.

Joffre

Santolaria

Calise

Al Saati

Hudrisier

Romagnoli

van Meerwijk

. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14(1):88–92.

Siu

JHY

Surendrakumar

Richards

Pettigrew

. T cell allorecognition pathways in solid organ transplantation. Front Immunol. 2018;9:2548.

Kong

Chen

Liu

Wang

Guo

. Adenovirus-IL-10 relieves chronic rejection after mouse heart transplantation by inhibiting miR-155 and activating SOCS5. Int J Med Sci. 2023;20(2):172–85.

Glinton

DeBerge

Yeap

Zhang

Forbess

Luo

Thorp

. Acute and chronic phagocyte determinants of cardiac allograft vasculopathy. Semin Immunopathol. 2018;40(6):593–603.

Garbade

Barten

Bittner

Mohr

. Heart transplantation and left ventricular assist device therapy: two comparable options in end-stage heart failure? Clin Cardiol. 2013;36(7):378–82.

Stehlik

Edwards

Kucheryavaya

Benden

Christie

Dobbels

Kirk

Rahmel

Hertz

. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report–2011. J Heart Lung Transplant. 2011;30(10):1078–94.

10.

Carrillo-Salinas

Ngwenyama

Anastasiou

Kaur

Alcaide

. Heart inflammation: immune cell roles and roads to the heart. Am J Pathol. 2019;189(8):1482–94.

11.

LaRosa

Rahman

Turka

. The innate immune system in allograft rejection and tolerance. J Immunol. 2007;178(12):7503–509.

12.

Kopecky

Dun

Amrute

Lin

Bredemeyer

Terada

Bayguinov

Koenig

Frye

Fitzpatrick

JAJ

Kreisel

, et al Donor macrophages modulate rejection after heart transplantation. Circulation. 2022;146(8):623–38.

13.

Toldo

Quader

Salloum

Mezzaroma

Abbate

. Targeting the innate immune response to improve cardiac graft recovery after heart transplantation: implications for the donation after cardiac death. Int J Mol Sci. 2016;17(6):958.

14.

Munn

Mellor

. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147–54.

15.

Liu

Bizargity

Hancock

Visner

. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. J Immunol. 2009;183(2):1022–31.

16.

Mulley

Wee

Dodge

Christiansen

Simeonovic

Ierino

Sandrin

. Local expression of IDO, either alone or in combination with CD40Ig, IL10 or CTLA4Ig, inhibits indirect xenorejection responses. Xenotransplantation. 2008;15(3):174–83.

17.

Liu

Fletcher

Visner

. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med. 2006;173(5):566–72.

18.

Hill

Zagani

Voisine

Usal

Anegon

. Nitric oxide and indoleamine 2,3-dioxygenase mediate CTLA4Ig-induced survival in heart allografts in rats. Transplantation. 2007;84(8):1060–63.

19.

Sucher

Fischler

Oberhuber

Kronberger

Margreiter

Ollinger

Schneeberger

Fuchs

Werner

Watschinger

Zelger

, et al IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. J Immunol. 2012;188(1):37–46.

20.

Wiśnicki

Donizy

Remiorz

Janczak

Krajewska

Banasik

. Significance of indoleamine 2,3-dioxygenase expression in the immunological response of kidney graft recipients. Diagnostics (Basel). 2022;12(10):2353.

21.

Tian

Chen

Huan

Shen

Xiong

Wang

Miao

. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine. Cell Death Dis. 2019;10(8):557.

22.

Xie

Zhou

Yan

. Exosomes derived from IDO1-overexpressing rat bone marrow mesenchymal stem cells promote immunotolerance of cardiac allografts. Cell Transplant. 2018;27(11):1657–83.

23.

Cornelissen

Maijenburg

Nolte

Voermans

. Organ-specific migration of mesenchymal stromal cells: who, when, where and why. Immunol Lett. 2015;168(2):159–69.

24.

Brennan

Layrolle

Mooney

. Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration. Adv Funct Mater. 2020;30(37):1909125.

25.

Zhang

Chen

Zhang

Cao

Gao

. Transplantation of human mesenchymal stem-cell-derived exosomes immobilized in an adhesive hydrogel for effective treatment of spinal cord injury. Nano Lett. 2020;20(6):4298–305.

26.

Sheng

Zhao

Zhou

Duan

Cao

, et al Bone marrow mesenchymal stem cell-derived exosomes accelerate functional recovery after spinal cord injury by promoting the phagocytosis of macrophages to clean myelin debris. Front Cell Dev Biol. 2021;9:772205.

27.

Fan

Guan

Xiao

Wen

Wang

Liu

Luo

Tan

Zhou

, et al Exosome-functionalized polyetheretherketone-based implant with immunomodulatory property for enhancing osseointegration. Bioact Mater. 2021;6(9):2754–66.

28.

Barile

Moccetti

Marbán

Vassalli

. Roles of exosomes in cardioprotection. Eur Heart J. 2017;38(18):1372–79.

29.

Zhang

Guo

Chen

Cui

. The BMSC-derived exosomal lncRNA Mir9-3hg suppresses cardiomyocyte ferroptosis in ischemia-reperfusion mice via the Pum2/PRDX6 axis. Nutr Metab Cardiovasc Dis. 2022;32(2):515–27.

30.

Liu

Yuan

Yang

Cai

. miRNA profiling of exosomes from spontaneous hypertensive rats using next-generation sequencing. J Cardiovasc Transl Res. 2019;12(1):75–83.

31.

Yang

Nadithe

. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6(4):287–96.

32.

Shen

Liu

Cai

Kim

Weintraub

Liu

Tang

. Transplantation of cardiac mesenchymal stem cell-derived exosomes promotes repair in ischemic myocardium. J Cardiovasc Transl Res. 2018;11(5):420–28.

33.

Chen

Liu

Guo

Zhang

Zhu

Shu

. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. 2022;30(10):3133–54.

34.

Luther

Haar

McGuinness

Wang

Lynch Iv

Phan

Song

Shen

Gardner

Kuffel

Ren

, et al Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells. J Mol Cell Cardiol. 2018;119:125–37.

35.

Meirelles Lda

Nardi

. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol. 2003;123(4):702–11.

36.

Beetz

Kolb

Buck

Trautewig

Timrott

Vondran

FWR

Meder

Löbbert

Hundrieser

Klempnauer

Bektaş

, et al Recipient natural killer cells alter the course of rejection of allogeneic heart grafts in rats. PLoS ONE. 2019;14(8):e0220546.

37.

Jia

Xiang

Liu

Zhang

Shao

Hong

Quan

. TMT-based quantitative proteomic analysis of cumulus cells derived from vitrified porcine immature oocytes following in vitro maturation. Theriogenology. 2020;152:8–17.

38.

Stryiński

Mateos

Pascual

González

ÁF

Gallardo

Łopieńska-Biernat

Medina

Carrera

. Proteome profiling of L3 and L4 Anisakis simplex development stages by TMT-based quantitative proteomics. J Proteomics. 2019;201:1–11.

39.

Sun

Wang

Fan

Yang

Meng

Niu

Guo

Tran

Zhang

Jiang

, et al Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma. J Gene Med. 2023;26:e3608.

40.

Ritchie

Phipson

Law

Shi

Smyth

. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

41.

Love

Huber

Anders

. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

42.

Ito

Murphy

. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e79.

43.

Wang

Zhuang

Jiang

Zou

Wang

Fan

. Unveiling the key genes, environmental toxins, and drug exposures in modulating the severity of ulcerative colitis: a comprehensive analysis. Front Immunol. 2023;14:1162458.

44.

Chen

Zhou

Sun

. An immune-related gene prognostic index for head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27(1):330–41.

45.

Zhou

Liu

Zeng

Chen

Liu

. A pan-cancer analysis of CD161, a potential new immune checkpoint. Front Immunol. 2021;12:688215.

46.

The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330–38.

47.

Kanehisa

Sato

Kawashima

Furumichi

Tanabe

. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457–62.

48.

Shannon

Markiel

Ozier

Baliga

Wang

Ramage

Amin

Schwikowski

Ideker

. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.

49.

Wang

Saga

Mizukami

Sato

Nonaka

Fujiwara

Takei

Machida

Takikawa

Ozawa

Suzuki

. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012;40(4):929–34.

50.

Iken

Liu

Bizargity

Wang

Hancock

Visner

. Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells. Am J Respir Cell Mol Biol. 2012;47(4):405–16.

51.

Sun

Yuan

Zhao

Zhang

Liu

Dai

. Mechanism of indoleamine 2, 3-dioxygenase inhibiting cardiac allograft rejection in mice. J Cell Mol Med. 2020;24(6):3438–48.

52.

Wiśnicki

Donizy

Hałoń

Wawrzonkowski

Janczak

Krajewska

Banasik

. Indoleamine 2,3-dioxygenase 1 (IDO1) in kidney transplantation: a Guardian against rejection. J Clin Med. 2023;12(24):7531.

53.

Schietinger

Greenberg

. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51–60.

54.

Cervio

Barile

Moccetti

Vassalli

. Exosomes for intramyocardial intercellular communication. Stem Cells Int. 2015;2015:482171.

55.

Nasser

Masood

Adlat

Gang

Zhu

Chen

Zhu

. Mesenchymal stem cell-derived exosome microRNA as therapy for cardiac ischemic injury. Biomed Pharmacother. 2021;143:112118.

56.

Shao

Zhang

Lan

Wang

Zhang

Xiao

Meng

Geng

. MiRNA-sequence indicates that mesenchymal stem cells and exosomes have similar mechanism to enhance cardiac repair. Biomed Res Int. 2017;2017:4150705.

57.

Huang

. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med. 2018;22(12):5768–75.

58.

Novák

Macháčková

Krejčí

Bienertová-Vašků

Slabý

. MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice. Theranostics. 2021;11(12):6058–73.

59.

Raschzok

Reutzel-Selke

Schmuck

Tannus

Morgul

Dietel

Leder

Struecker

Lippert

Sallmon

Schmelzle

, et al microRNA signatures in peripheral blood fail to detect acute cellular rejection after liver transplantation. Biomarkers. 2016;21(8):699–707.

60.

Yang

Steward

Sweet

Danziger-Isakov

Heeger

Mohanakumar

. Role of circulating MicroRNAs in the immunopathogenesis of rejection after pediatric lung transplantation. Transplantation. 2017;101(10):2461–68.

61.

Nowak

Tardivel

Nguyen-Khoa

Abreu

Allaoui

Fournier

Chaminade

Paul

Lacour

. Mycophenolate mofetil and rapamycin induce apoptosis in the human monocytic U937 cell line through two different pathways. J Cell Biochem. 2017;118(10):3480–87.

62.

Sangaletti

Talarico

Chiodoni

Cappetti

Botti

Portararo

Gulino

Consonni

Sica

Randon

Di Nicola

, et al SPARC is a new myeloid-derived suppressor cell marker licensing suppressive activities. Front Immunol. 2019;10:1369.

63.

Vafadari

Hesselink

Cadogan

Weimar

Baan

. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. Transplantation. 2012;93(12):1245–51.

64.

Piccinni

Raghupathy

Saito

Szekeres-Bartho

. Cytokines, hormones and cellular regulatory mechanisms favoring successful reproduction. Front Immunol. 2021;12:717808.

65.

Vanhoutte

Schips

Grimes

Baldwin

Brody

Accornero

Sargent

Molkentin

. Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy. Nat Commun. 2021;12(1):3928.

66.

Chen

Lai

Zhu

Hou

Wang

Chen

Wang

Tang

. Cardioprotective effect of decorin in type 2 diabetes. Front Endocrinol (Lausanne). 2020;11:479258.

67.

Sznajer

Keren

Baumann

Pereira

Alberti

Elion

Cavé

Verloes

. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics. 2007;119(6):e1325–31.

68.

Liu

Chen

. Identification of important genes related to ferroptosis and hypoxia in acute myocardial infarction based on WGCNA. Bioengineered. 2021;12(1):7950–63.

69.

Badi

Salcman

Taylor

Rana

Kermani

Riley

Worsley

Mumby

Dahlen

Cousins

Bulfone-Paus

, et al IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma. Allergy. 2023;78(1):156–67.

70.

Glinton

Lantz

Grigoryeva

DeBerge

Liu

Febbraio

Kahn

Oliver

Thorp

. Macrophage-produced VEGFC is induced by efferocytosis to ameliorate cardiac injury and inflammation. J Clin Invest. 2022;132(9):e140685.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB